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Abstract
Background: Adenosine is generated in response to cellular stress and damage and is elevated in the lungs of patients with
chronic lung disease. Adenosine signaling through its cell surface receptors serves as an amplifier of chronic lung disorders,
suggesting adenosine-based therapeutics may be beneficial in the treatment of lung diseases such as chronic obstructive
pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Previous studies in mouse models of chronic lung
disease demonstrate that the key components of adenosine metabolism and signaling are altered. Changes include an up-
regulation of CD73, the major enzyme of adenosine production and down-regulation of adenosine deaminase (ADA), the
major enzyme for adenosine metabolism. In addition, adenosine receptors are elevated.
Methodology/Principal Findings: The focus of this study was to utilize tissues from patients with COPD or IPF to examine
whether changes in purinergic metabolism and signaling occur in human disease. Results demonstrate that the levels of CD73
and A2BRareelevatedinsurgicallungbiopsiesfromsevereCOPDandIPFpatients.Immunolocalizationassaysrevealedabundant
expression of CD73 and the A2BR in alternatively activated macrophages in both COPD and IPF samples. In addition, mediators
that are regulated by the A2BR, such as IL-6, IL-8 and osteopontin were elevated in these samples and activation of the A2BRo n
cells isolated from the airways of COPD and IPF patients was shown to directly induce the production of these mediators.
Conclusions/Significance: These findings suggest that components of adenosine metabolism and signaling are altered in a
manner that promotes adenosine production and signaling in the lungs of patients with COPD and IPF, and provide proof of
concept information that these disorders may benefit from adenosine-based therapeutics. Furthermore, this study provides the
first evidence that A2BR signaling can promote the production of inflammatory and fibrotic mediators in patients with these
disorders.
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Introduction
Destructive lung disorders such as chronic obstructive pulmonary
disease (COPD) and interstitial lung disease such as idiopathic
pulmonary fibrosis (IPF) affect millions of individuals and result in
billions of dollars in annual health care cost. Considerable
information has been gathered concerning the mechanisms that
promote inflammatory and tissue remodeling processes in these
disorders; however, relatively little is known about the pathways
that drive their progressive and chronic nature. Deregulated or
overactive wound healing pathways are hypothesized to contribute
to the excessive remodeling responses that are seen in chronic lung
diseases [1,2]. Extracellular adenosine is a signaling molecule that is
produced in response to cell damage and can regulate tissue injury
and repair [3]. Consistent with this, adenosine levels are elevated in
the lungs of patients with chronic lung disease [4,5,6], where it is
hypothesized to regulate the balance between tissue repair and
excessive airway remodeling [7]. Adenosine influences cell function
by engaging G-protein coupled adenosine receptors that access a
variety of intracellular signaling pathways [8]. Four adenosine
receptors have been described: A1R, A2AR, A2BR and A3R. These
receptors may have different affinities for adenosine and different
cellular and tissue distribution. Levels of adenosine receptors are
altered in the lungs of asthmatics [9,10] and COPD patients [10,11]
and a recent study has shown that the A2BR is increased in
remodeled airway epithelial cells of rapidly progressing IPF patients
[12].
It has been recognized that adenosine may also play a critical
role in the pathogenesis of chronic inflammatory disorders of
the airways such as asthma and COPD.[13,14]. For example,
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patients with asthma or COPD [15,16], while having no effect on
normal individuals, suggesting a fundamental difference with regard
to adenosine signaling in these patients. Activation of adenosine
receptors can also influence the activity of cell types that play a
central role in chronic lung disease including mast cells [17],
eosinophils [10], macrophages [18], airway epithelial cells [19],
pulmonary fibroblasts [20], and airway smooth muscle cells [21].
Moreover, recent studies directly demonstrate the role of adenosine
in the regulation of pulmonary fibrosis. Exposure of human
pulmonary fibroblasts to adenosine promotes their differentiation
into myofibroblasts through activation of the A2BR [20]. In
addition, activation of A2BR promotes the production of fibronectin
from type II alveolar epithelial cells [22], a process that can impact
pulmonary fibrosis. Collectively, these studies demonstrate that
adenosine can regulate processes that influence pulmonary fibrosis
and implicate the A2BR as a pro-fibrotic receptor.
Examination ofadenosine levelsinanimal modelsofchronic lung
disease corroborate with these findings in humans. Transgenic mice
that over express the Th2 cytokines IL-4 or IL-13 in the lungs
develop progressive pulmonary inflammation and injury character-
ized by eosinophilic and monocytic infiltrates, fibrosis and alveolar
airspace destruction in association withincreases of adenosine in the
lungs [23,24]. In addition, adenosine levels are elevated in the lungs
of mice exposed to the fibrosis inducing agent bleomycin [25] or
following chronic ovalbumin exposure [26]. Lastly, there are corre-
lations between the degree of inflammation and damage and
adenosine accumulations in adenosine deaminase (ADA)-deficient
mice [27]. In these animal models, levels of key components of
adenosine metabolism (Figure 1) and signaling are altered. These
changes include the up-regulation of ecto-59-nucleotidase (CD73)
[25], one of the key enzymes of adenosine production, and the
down-regulation of ADA, one of the key enzymes for adenosine
metabolism [23,24]. In addition, we have observed up-regulation of
pro-inflammatory and pro-fibrotic adenosine receptors in these
models [23,24,25,27,28]. Moreover, therapeutic strategies to lower
adenosine levels or inhibit adenosine receptors lead to improve-
ment in pulmonary pathologies in many of these animal models
[23,24,27,29,30,31]. These findings suggest that adenosine-based
therapeutics may be beneficial in the treatment of chronic lung
diseases such as COPD and IPF.
The objective of the current study was to determine whether
adenosine metabolism and signaling are altered in patients with
COPD and/or IPF. Our hypothesis was that purinergic
metabolism and signaling components are altered in a manner
that promotes adenosine production in tissue samples from
patients with COPD and IPF. Our results demonstrate that
CD73 and the A2BR are elevated in lung biopsy samples from
patients with Stage 4 COPD and Severe IPF compared to patients
with preserved lung function. Expression of CD73 and the A2BR
were localized predominantly to alternatively activated macro-
phages in airspaces. These elevations were associated with
significant alterations in the expression of pro-inflammatory
mediators known to be driven by A2BR signaling, and ex vivo
studies demonstrated that activation of A2BR can influence the
production of key inflammatory and fibrotic mediators from
macrophages isolated from these patients.
Methods
Subjects
The use of human material for this study was reviewed by the
University of Texas Health Science Center at Houston Committee
for the Protection of Human Subjects. All studies in tissues were
from existing samples already collected and deidentified and were
therefore considered exempt. The analysis of lavage isolated from
patients was also reviewed and approved by this committee with
no ethical concerns. Surgical lung biopsy tissue samples were
obtained from the Lung Tissue Research Consortium (LTRC)
(Table 1). Patients were classified as Stage 0 COPD, Stage 4
COPD, Mild IPF and Severe IPF according to spirometry,
pathological examination and high resolution CT scan (Figure 2).
Stage 0 COPD and Mild IPF patients with preserved lung
functions were used as controls in comparison to Stage 4 COPD
and Severe IPF patients. For ex vivo culture experiments,
macrophages were isolated form lavage fluid collected from Stage
4 COPD or Severe IPF patients that were lavaged as part of
routine diagnostic procedures.
Figure 1. Key components of adenosine metabolism and signaling. In response to cellular stress and damage, ATP is released into the
extracellular space and is rapidly dephosphorylated by extracelluar nucleotidases. CD73 catalyzes the formation of extracellular adenosine from AMP.
Extracellular adenosine can interact with seven-transmembrane adenosine receptors, A1R, A2AR, A2BR, and A3R, which are coupled by heterotrimeric G
proteins to various second messenger systems, or it can be transported into cells via facilitated nucleoside transporters, such as ENT1. Both
extracellular and intracellular adenosine can be deaminated to inosine by adenosine deaminase (ADA). Intracellular adenosine can be secreted or
phosphorylated back to ATP. The first step in this process is catalyzed by adenosine kinase (AK).
doi:10.1371/journal.pone.0009224.g001
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Total RNA was isolated from frozen lung tissue using Trizol
reagent (Invitrogen Corp.). RNA was purified through an RNA-
purification column (Qiagen) and treated using RNase-free DNase
(Invitrogen Corp.). Transcript levels were quantified using Taq-
man real-time quantitative RT-PCR. Primer sequences for the
transcripts examined are found in Table 2. Specific transcript
levels were determined through comparison to a standard curve
generated from the PCR amplification of template dilutions, and
normalized to 18S ribosomal RNA and presented as mean
transcript levels expressed as %18S RNA.
Enzyme Activity Assay
Lungs were homogenized and lysed on ice with protein lysis
buffer (50mM Tris pH7.4, 150mM NaCl, 1% Triton-X 100,
0.1% SDS, 0.5% Na deoxycholate) freshly supplemented with 1X
protease inhibitor cocktail (Roche Diagnostics). Lysates were
vigorously vortexed and cleared by centrifugation at 14,000rpm
for 15 min at 4uC. To quantify CD73 enzyme activity, 5 mgo f
protein extracts were incubated with 100 mM AMP at 37uC for
30 min in the presence of 1 mM deoxyconformycin in HEPES
buffer, with or without 100 mM CD73 inhibitor adenosine- 59-O -
(a, b- methylenediphosphate) (AOPCP). To quantify ADA enzyme
activity, 10 of mg protein extracts were incubated with 0.2 mM
adenosine at 37uC for 60 min in HEPES buffer with or without
1 mM deoxyconformycin, an ADA inhibitor. Heat-inactive protein
extracts were used as negative controls. Reactions were terminated
at 95uC for 5 min. Reaction mixtures were then analyzed by
reversed-phase (C18) HPLC, which permitted direct separation,
identification, and quantification of enzymatic products [27].
Enzyme specific activity is given as nmol product formed per min
per mg protein (nmole/min/mg protein).
Histology and Immunostaining
HOPE or paraformaldyhyde fixed lung samples from the same
location as RNA and protein lysates were dehydrated, and
embedded in paraffin, and sections (5 mm) were collected on
microscope slides and stained with H&E (Shandon-Lipshaw)
according to manufacturer’s instructions. For CD73 immunostain-
ing, HOPE-fixed sections were deparaffinized in isopropanol at
60uC and rehydrated in 70% acetone. Rehydrated slides were
quenched with 1% hydrogen peroxide and endogenous avidin and
biotin blocked with a Biotin Blocking System (DAKO Corp.). Slides
were incubated with mouse anti-human CD73 antibody (Hycult
Biotechnology, 1:50 dilution, overnight at 4uC). For A2BR
immunostaining, rehydrated slides were quenched with 1%
hydrogen peroxide, antigen retrieval performed (Dako Corp.),
and endogenous avidin and biotin blocked with a Biotin Blocking
System (DAKO Corp.). Slides were incubated with rabbit anti-
human A2BR Antibody (Chemicon, 1:500 dilution, 1 hr at room
temperature). Sections were incubated with ABC Streptavidin
reagents and appropriate secondary antibodies, then developed
with 3, 39-diaminobenzidine (Sigma-Aldrich) and counterstained
with methyl green. The number of positively stained inflammatory
cells in each group was performed by counting positive cells in 20
images of each lung section at 10X magnification using Image Pro
Plus software (Cybernetics). For immunofluorescence on tissue
sections, rehydrated slides were fixed in 1:1 acetone-methanol and
treated with 1% NaBH4. Slides were blocked in 1% BSA, and
incubated overnight at 4uC with the primary antibodies. For
immunofluorescence on primary human macrophages, cells were
cytospun and fixed in 3.7% paraformaldehyde in PBS and
permeabilized in cold Methanol. Slides were blocked with 1%
rabbit serum and incubated overnight at 4uC with the primary
antibodies. Primary antibodies include: mouse anti-human CD73
antibody (Hycult Biotechnology, 1:50 dilution), Rabbit Anti-human
A2BR Antibody (Chemicon, 1:500 dilution), rat anti-human MMR
(CD206) antibody (R&D Systems, 1:50 dilution). Sections and cells
were incubated with the following secondary antibodies: Alexa
Fluor 488 rabbit anti-mouse IgG, Alexa Fluor 488 goat anti-rabbit
IgG, Alexa Fluor 568 goat anti-rat IgG (Intritrogen) then
coversliped with Vectashield with DAPI (Vector Laboratories).
In vitro Stimulation of Human Primary Alveolar
Macrophages
Primary alveolar macrophages were obtained from BAL fluid of
stage 4 COPD or severe IPF patients. BAL fluid was spun and cell
pellets were resuspended in RPMI1640 containing 10% FBS and
10,000 U/ml penicillin/streptomycin. Cells were portioned into
aliquots of 2610
5 cells/well, allowed to adhere for 4 hours at 37uC
5% CO2, and then rinsed twice with RPMI1640 without FBS.
Cells were either pre-incubated with 100 nM CVT-6883 (selective
A2BR antagonist) for 30 min followed by NECA or incubated with
NECA alone (in DMSO, 10 mM NECA/well; Tocris Bioscience)
for 12 h at 37uC5 %C O 2. Tissue culture supernatants were
collected and IL-8 and IL-6 levels were quantified using Human
Quantikine ELISA kits (R&D Systems).
Statistics
Groups were compared by analysis of variance; follow-up
comparisons between groups were conducted using 2-tailed Student’s
t test. Associations between transcript levels of two genes were
established by linear regression. Correlation significances were
analyzed using Pearson correlation calculator software. Values are
expressed as mean 6 SEM. A p value of #0.05 was considered to
be significant.
Results
Transcript Levels of Components of Adenosine Metabolism and
Signaling are Altered in the Lungs of COPD and IPF Patients














N 4 10 10 10
Age, yrs 69 (61–78) 60 (50–77) 50 (44–63) 54 (26–62)
Sex, M/F 1/3 6/4 6/4 7/3
Pack-yrs smoking 25 (25–50)








FEV1, % pred 86 (84–89) 92 (66–109) 20 (12–40)* 38 (30–46)
#
FVC, % pred 107 (80–113) 89 (80–105) 54 (13–77)* 38 (25–43)
#
FEV1/FVC, % 60 (50–80) 80 (60–90) 30 (20–60)* 90 (70–100)
Data are presented as median (interquartile range). M/F: male/female; FEV1:
forced expiratory volume in one second; % pred: % predicted; FVC: forced vital
capacity.
1: Stage 0 COPD is defined as FEV1, % pred .80;
2: Mild IPF is defined
as FVC, % pred .80;
3: Stage 4 COPD is defined as FEV1, % pred ,50;
4: Severe
IPF is defined as FVC, % pred ,50;
a: data available for 3/4 Stage 0 COPD
patients;
b: data available for 5/10 Mild IPF patients;
c: data available for 9/10
Stage 4 COPD patients;
d: data available for 4/10 Severe IPF patients;
e: data
available for 9/10 Mild or Severe IPF patients. *: p,0.05 compared with Stage 0
COPD patients;
#:p ,0.05 compared with Mild IPF patients.
doi:10.1371/journal.pone.0009224.t001
Adenosine and Lung Disease
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9224Figure 2. Lung histopathology and high-resolution CT scans. Representative H&E staining and hign-resolution CT scan images showing: (A) A
Stage 0 COPD patient with preserved lung function. (B) A Mild IPF patient with preserved lung function. (C) A Stage 4 COPD patient. (D) A Severe IPF
patient. Sections are representative of 10–14 different patients from each group. The yellow boxes in the CT scan images represent the approximate
location of the surgical biopsies for obtaining tissues sections frozen material for analysis in these examples.
doi:10.1371/journal.pone.0009224.g002
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in mouse models of chronic lung disease in association with
elevated levels of adenosine [23,24,25,27] (Figure 1). Total RNA
was isolated from surgical lung biopsy specimens and real-time
RT-PCR was performed to quantify key components of adenosine
metabolism and signaling. Results demonstrated a 3 fold increase
of CD73 transcripts in RNA extracts from Severe IPF and Stage 4
COPD patients compared to Mild IPF and Stage 0 COPD
patients with preserved lung function (Figure 3A). However, the
transcript levels of ADA, AK and ENT1 were not altered
(Figure 3B-D). All four adenosine receptors were detectable in
subjects with preserved lung function (Figure 3E); however, only
transcript levels for the A2BR were significantly increased in Severe
IPF and Stage 4 COPD patients (Figure 3E). Interestingly,
smoking status had no influence on the level of adenosine receptor
expression in the IPF patients examined (data not shown).
Collectively, these findings demonstrate elevations in components
of adenosine production and signaling in the lungs of patients with
progressive chronic lung diseases.
CD73 and ADA Enzymatic Activities Are Altered in the
Lungs of COPD and IPF Patients
To examine alterations in enzymatic activities of the key enzymes
of adenosine metabolism, protein extracts were made from surgical
lung biopsy specimens and enzymatic activities of CD73 and ADA
were determined using HPLC. The enzymatic activity of CD73 was
increased by 2 fold and 2.5 fold, respectively, in Stage 4 COPD and
Severe IPF patients compared to subjects with preserved lung
function (Figure 4A). This finding was consistent with the increases
in CD73 transcripts noted and suggests an increased capacity for
extracellular adenosine generation in Stage 4 COPD and Severe
IPF patients. In addition, there was a significant decrease in ADA
enzymatic activity in Severe IPF patients, and Stage 4 COPD
patients (Figure 4B). This observation suggests that there may be
post-transcriptional regulation of ADA activity that may contribute
to permissive environment for adenosine accumulation.
Cellular Localization of CD73 and A2BR Expression in
Lung Tissue from COPD and IPF Patients
To identify the cellular localization of key components of
adenosine metabolism and signaling, tissue sections from surgical
lung biopsies were subjected to immunostaining with antibodies
against CD73 and the A2BR. In subjects with preserved lung
function, CD73 was expressed on inflammatory cells as well as
endothelial cells (Figure 5A and 5B). In Stage 4 COPD patients,
CD73 was expressed on inflammatory cells and endothelial cells
(Figure5C, arrow), while inSevereIPF patients, CD73 waslocalized
to inflammatory cells, endothelial cells and hyperplastic cells in
remodeled airways (Figure 5D, red arrow). Quantification of CD73
positive inflammatory cells revealed significant increases in Stage 4
COPD and Severe IPF patients compared to COPD and IPF
patients with preserved lung function (Figure 5E). A2BR expression
was localized to inflammatory cells, mostly macrophages, in both
Stage 0 and 4 COPD patients (Figure 6A and 6C). In IPF patients,
A2BR immunoreactivity was found on inflammatory cells, stromal
cells (Figure 6B and 6D) as well as hyperplastic cells in remodeled
airways (Figure 6F). Quantification of A2BR positive inflammatory
cells revealed significant increases in Stage 4 COPD and Severe IPF
patients compared to COPD and IPF patients with preserved lung
function (Figure 6E).
Alternatively activated macrophages, also known as M2 macro-
phages, are involved in microenvironments exhibiting prolonged
inflammation and fibrosis, where they produce mediators that
contribute to disease maintenance and progression [32,33]. To
determine if M2 macrophages within the lungs of COPD and IPF
patients express CD73 and the A2BR, co-localization studies using
an M2 macrophage marker, CD206 and either CD73 or A2BR
antibodies were conducted on sections from these patients. Results
demonstratedthat M2macrophagesexpressboth CD73 (Figure7A)
and the A2BR (Figure 7B) in COPD and IPF patients.
Transcript Levels of Pro-inflammatory Mediators
Downstream of Adenosine Signaling Are Altered in the
Lungs of COPD and IPF Patients
A2BR signaling can regulate the expression of inflammatory and
fibrotic mediators in cell types and lung tissue associated with
chronic lung disease [30,34,35,36,37,38,39]. Total RNA was
isolated from lung biopsy specimens and real time RT-PCR was
performed to quantify key mediators that have been shown to be
regulated by A2BR signaling. Results demonstrated that transcript
levels of IL-6, IL-8 and OPN were all increased in both Stage 4
COPD and Severe IPF patients compared to subjects with
preserved lung function (Figure 8A-C). These findings demon-
strate that pro-inflammatory and pro-fibrotic mediators that can
be regulated by A2BR signaling are elevated in COPD and IPF
patients that exhibit increased A2BR expression.
To investigate the associations between these components of
adenosine metabolism and signaling and downstream effecter
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PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9224Figure 3. Expression of components of adenosine metabolism and signaling. Transcript levels of various enzymes in adenosine
metabolism, and adenosine receptors were quantified in lung RNA extracts from patients using quantitative RT-PCR. Shown are levels of (A) CD73, (B)
ADA, (C) AK, (D) ENT1, (E) Adenosine receptors. Results are presented as mean percentage of 18sRNA transcripts 6 SEM. *p#0.05 versus Stage 0
COPD. #p#0.05 versus Mild IPF. n=4 (Stage 0 COPD), n=10 (Mild IPF), n=8 (Stage 4 COPD and Severe IPF).
doi:10.1371/journal.pone.0009224.g003
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fibrotic mediator transcript levels were determined using linear
regression. CD73 levels demonstrated a significant correlation with
A2BR transcript levels (Figure 9A). Although significant correlations
were not found in COPD patients, in IPF patients, the transcript
levelsof IL-6and IL-8exhibited a significant correlation with CD73
(Figure 9B and C), while the transcript levels of IL-8 and OPN
significantly correlated with A2BR expression (Figure 9D and E).
A2BR Signaling on M2 Macrophages Contributes to the
Production of IL-8 and IL-6
To determine if the A2BR on M2 macrophages is directly
involved in the induction of pro-inflammatory/fibrotic mediators,
human primary alveolar macrophages were isolated from the BAL
fluid of Severe IPF and Stage 4 COPD patients. Co-localization
studies using an M2 macrophage marker, CD206 and either
CD73 or A2BR antibodies were conducted on cells isolated from a
patient with IPF to validate that the isolated cells were
predominantly M2 macrophages and to demonstrate that they
express both CD73 and the A2BR (Figure 10A). Primary alveolar
macrophages were placed in culture and pretreated with the A2BR
antagonist (CVT-6883) before NECA exposure. This resulted in a
loss of NECA-stimulated increases in IL-8 and IL-6 production
(Figure 10B). Interestingly, A2BR antagonism alone was able to
decrease baseline production of IL-8 and IL-6 in cell cultures from
the IPF patients, suggesting these cells are already activated and
adenosine produced from these cells can activate the A2BR and
contribute to IL-8 and IL-6 production (Figure 10B). These
findings demonstrate that IL-8 and IL-6 expression is regulated by
activation of the A2BR on M2 alveolar macrophages in the lungs of
IPF and COPD patients.
Discussion
Adenosine is a signaling molecule produced as a result of cell
stress or damage. Several studies demonstrate elevated adenosine
levels in patients with chronic lung disease. Adenosine levels are
elevated in lavage fluid collected from asthmatics [4], in the
exhaled breath condensate of patients with allergic asthma [5], in
plasma of asthmatic subjects following bronchial provocation with
allergen [40], and in patients with exercise-induced asthma [41].
In addition to asthma, adenosine levels are elevated in sputum
samples from cystic fibrosis patients [42]. Consistent with this,
adenosine levels are elevated in various mouse models exhibiting
features of chronic lung disease [23,24,25,26]. In addition, the
levels of key components of adenosine metabolism and signaling
are altered in these mouse models in a manner that promotes
adenosine accumulation and tissue-destructive adenosine receptor
signaling, a process known as ‘‘purinergic remodeling’’. Our
hypothesis was that purinergic remodeling also exists in patients
with Stage 4 COPD and/or Severe IPF relative to patients with
less severe forms of these diseases. Confirmation of this would
provide proof of concept information that chronic lung diseases
such as COPD and IPF may benefit from treatment with
adenosine based therapeutics.
CD73 is the major enzyme for extracellular adenosine pro-
duction. CD73 levels are up-regulated in the lungs of mouse
models with chronic lung disease including ADA-deficient mice
and mice exposed to bleomycin [25,27]. In addition, bronchial
epithelial cells from patients with cystic fibrosis exhibit increased
CD73 activity [43]. These findings suggest that the up-regulation
of CD73 is an important purinergic remodeling response in
environments where adenosine has been shown to regulate
disease. In the current study, we observed that transcript levels
of CD73 are elevated in both Stage 4 COPD and Severe IPF
patients compared with subjects with preserved lung function.
Consistent with this, the enzymatic activity of CD73 was sig-
nificantly increased in both Stage 4 COPD and Severe IPF
patients. CD73 was expressed on endothelial cells and inflamma-
tory cells in normal lungs, and endothelial cells, inflammatory cells
and hyperplastic epithelial cells in remodeled airways in diseased
lungs. These findings suggest that there is an increased capacity for
adenosine production in the lungs of Stage 4 COPD and Severe
IPF patients. The levels of adenosine have not been measured in
the lungs of COPD and IPF patients due to problems associated
with the rapid metabolism of adenine nucleotides and adenosine.
Figure 4. CD73 and ADA enzymatic activity. CD73 (A) and ADA (B) enzyme activity were quantified in lung protein extracts from patients.
Reaction mixtures were separated, identified, and quantified by HPLC. Data are presented as mean nanomoles of substrate converted to product per
min per milligram of protein 6 SEM. *p#0.05 versus Stage 0 COPD. #p#0.05 versus Mild IPF. n=4 (Stage 0 COPD), n=10 (Mild IPF), n=8 (Stage 4
COPD and Severe IPF).
doi:10.1371/journal.pone.0009224.g004
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PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9224The ability to measure increases in CD73 provides a novel and
important means of determining the capacity of adenosine
generation. This study is the first to demonstrate this in the lungs
of patients with Stage 4 COPD and Severe IPF and suggest these
diseases are associated with increases in adenosine levels.
ADA is the major enzyme of adenosine metabolism [44]. It
deaminates adenosine to inosine both intracellularly and extracel-
lularly. Mice over-expressing the Th2 cytokines IL-4 or IL-13 in
their lungs exhibit features of COPD and pulmonary fibrosis in
association with adenosine elevations [23,24]. Interestingly, ADA
transcripts and enzymatic activity are selectively down-regulated
in the lungs of these mice suggesting a purinergic remodeling
response directed at promoting adenosine accumulations. Our
findings demonstrate that although the transcript levels of ADA
are not decreased in Severe IPF and Stage 4 COPD patients, the
enzymatic activity of ADA is significantly reduced in these
patients. ADA has been shown to be regulated both transcirption-
ally and post-transcriptionally [45]. Our results suggest that post-
transcriptional regulation of ADA mRNA might contribute to the
regulation of ADA in the lungs of IPF and COPD patients.
Potential mechanisms of post-transcriptional regulation include
the regulation of ADA mRNA translation efficiency by micro-
RNAs, enhanced protein stability or covalent modifications to the
protein such as phosphorylation, that could increase its enzymatic
activity. Little is known about the role of these processes in
regulating ADA enzymatic activity, and examining these mech-
Figure 5. Localization of CD73. Lung sections were stained with antibodies against CD73. (A) Lung section from a Stage 0 COPD patient. (B) Lung
section from a Mild IPF patient. (C) Lung section from a Stage 4 COPD patient. (D) Lung section from a Severe IPF patient. Sections are representative
of 10–14 different patients from each group. Scale bars=100 mm. (E) CD73 positive inflammatory cells were quantified in 20 images. Data are
presented as mean number of positive cells per 10X field 6 SEM. *p#0.05 versus Stage 0 COPD. #p#0.05 versus Mild IPF. n=4 (Stage 0 COPD),
n=10 (Mild IPF), n=8 (Stage 4 COPD and Severe IPF).
doi:10.1371/journal.pone.0009224.g005
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9224anisms could provide important insight into novel mechanisms of
purinergic remodeling in disease. Collectively, our findings suggest
that there is less adenosine metabolism in the lungs of Severe IPF
and Stage 4 COPD patients, which could contribute to adenosine
accumulations.
Adenosine regulates numerous cellular activities by engaging cell
surface adenosine receptors [8]. Researchconducted by us and others
have provided evidence that adenosine receptor expression is altered
in models of lung disease. The A1R, A2BRa n dA 3R are elevated
in the lungs of models exhibiting pulmonary fibrosis and alveolar
Figure 6. Localization of the A2BR. Lung sections were stained with antibodies against the A2BR. (A) Lung section from a Stage 0 COPD patient.
(B) Lung section from a Mild IPF patient. (C) Lung section from a Stage 4 COPD patient. (D) Lung section from a Severe IPF patient. Sections are
representative of 10–14 different patients from each group. Scale bars=100 mm. (E) A2BR positive inflammatory cells were quantified in 20 images.
Data are presented as mean number of positive cells per 10X field 6 SEM. *p#0.05 versus Stage 0 COPD. #p#0.05 versus Mild IPF. n=4 (Stage 0
COPD), n=10 (Mild IPF), n=8 (Stage 4 COPD and Severe IPF). (F) A2BR expression in hyperplastic airway epithelial cells (blue arrow) and fibroblasts
(red asterix). Scale bar=200 mm.
doi:10.1371/journal.pone.0009224.g006
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PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9224Figure 7. Expression of CD73 and the A2BR in M2 macrophages. Lung sections from COPD or IPF patients were reacted with antibodies
against CD73 (A, green) or the A2BR (B, green) together with the M2 macrophage marker CD206 (red). In the merged images, yellow represents co-
localization of CD73 or the A2BR and the M2 marker, blue is dapi stained nuclei. Sections are representative of 10–14 different patients from each
group. Scale bars=100 mm.
doi:10.1371/journal.pone.0009224.g007
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PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9224airspace destruction [23,24,29,46]. Interestingly, the A2AR, which is
down-regulated in these models, is largely an anti-inflammatory
adenosinereceptor[47].Thedifferentialexpressionofthesereceptors
in models of lung disease provides insight into the potential role of
adenosine signaling in COPD and pulmonary fibrosis. In the current
study, transcript levels of the A2BR were significantly elevated in both
Stage 4 COPD and Severe IPF patients. A2BRe x p r e s s i o nw a s
localized predominantly to inflammatory cells with some expression
noted on remodeled airway epithelial cells and fibroblasts in IPF
patients. The findings in IPF patients were consistent with a recent
study demonstrating that A2BR levels are elevated in a subset of
patients with rapidly progressing IPF [12]. In addition, our findings
demonstrating immunoreactivity in macrophages found in the
airways of COPD patients are consistent with a recent study by
Varani and colleagues [11]. However, there were differences between
the two studies regarding the relative levels of A2BR transcripts.
Whereas we demonstrate increases in only the A2BR in the lungs of
Stage 4 COPD patients, Varani and colleagues demonstrated
increases in transcript levels for the A2ARa n dA 3Ra n dd e c r e a s e d
levels of the A2BR [11]. The reason for these discrepancies are not
clear, but may be related to differences in disease severity and/or
smoking status of the patients in these two studies.
Figure 8. Expression of pro-inflammatory mediators. Transcript levels of various cytokines and chemokines were quantified in lung RNA
extracts from patients using quantitative RT-PCR. Shown are levels of (A) IL-6, (B) IL-8, (C) OPN. Results are presented as mean percentage of 18sRNA
transcripts 6 SEM. *p#0.05 versus Stage 0 COPD. #p#0.05 versus Mild IPF. n=4 (Stage 0 COPD), n=10 (Mild IPF), n=8 (Stage 4 COPD and Severe
IPF).
doi:10.1371/journal.pone.0009224.g008
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PLoS ONE | www.plosone.org 11 February 2010 | Volume 5 | Issue 2 | e9224The A2BR has the lowest affinity for adenosine and is therefore
likely activated under pathological conditions where adenosine
levels are increased [48]. A2BR activation has both anti- and pro-
inflammatory actions and both anti- and pro-fibrotic roles [7,49].
Despite the receptor’s homeostatic and protective functions during
the acute phase of lung injury [38,50], several studies have shown
that signaling through the A2BR can contribute to the pathology
and progressive nature of chronic lung diseases [20,30,39]. For
example, activation of the A2BR on pulmonary fibroblasts
promotes their differentiation into myofibroblasts and hence
increases the deposition of collagen and fibrosis [20]. Furthermore,
A2BR signaling increases the expression of fibronectin in airway
epithelial cells [22]. Activation of the A2BR can also promote the
expression or release of pro-inflammatory cytokines such as IL-4,
IL-8 and IL-13 [34,35,36], which may influence the chronic nature
of certain lung diseases. Moreover, the A2BR is responsible for
promoting the expression of IL-6, OPN and CXCL1 (mouse
homologue of IL-8) in mouse alveolar macrophages in lungs
exhibiting airspace enlargement and fibrosis [30,51]. Consistent
with these findings, we demonstrate here that transcript levels of IL-
6, OPN and IL-8 are elevated in the lungs of Stage 4 COPD and
Severe IPF patients. Moreover, we demonstrate that treatment with
a selective A2BR antagonist, CVT-6883 can prevent the release of
IL-6 and IL-8 from M2 macrophages isolated from these patients.
These findings, together with published observations that CVT-
6883 can reduce the levels of these mediators and prevent fibrosis
and airspace enlargement in mouse models of pulmonary injury
[30], suggest that this antagonist may be useful in treating patients
with COPD and IPF.
Although evidence of purinergic remodeling and A2BR driven
mediator expression was found in both IPF and COPD patients, it
is important to note that there were differences in these features
between diseases. For example, association studies demonstrated a
closerelationship between CD73 orA2BR expressionand IL-6,IL-8
Figure 9. Associations between the expression of CD73, A2BR and inflammatory mediators. The transcript levels of CD73 in individual
COPD and IPF patients were significantly associated with transcript levels of the A2BR (A). In IPF patients, the transcript levels of IL-6 (B) and IL-8 (C)
were significantly correlated with the transcript levels of CD73; the transcript levels of IL-8 (D) and OPN (E) were significantly correlated with the
transcript levels of A2BR.
doi:10.1371/journal.pone.0009224.g009
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PLoS ONE | www.plosone.org 12 February 2010 | Volume 5 | Issue 2 | e9224Figure 10. A2BR-dependent IL-8 and IL-6 expression in human primary alveolar macrophages. (A) Cells from an IPF patient were reacted
with antibodies against CD73 (A, upper panel, green) or the A2BR (A, lower panel, green) together with the M2 macrophage marker CD206 (red). In the
merged images, yellow represents co-localization of CD73 or the A2BR and the M2 marker, blue is dapi stained nuclei. (B) ELISA measurements of IL-8
and IL-6 production from macrophage cultures of IPF and COPD patients. Results are presented as mean concentrations of cytokines 6 SEM. *p#0.05
versus cells without any treatment.
#p#0.05 versus cells treated with NECA alone. n=6.
doi:10.1371/journal.pone.0009224.g010
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PLoS ONE | www.plosone.org 13 February 2010 | Volume 5 | Issue 2 | e9224and OPN expression in IPF patients but not in COPD patients.
This suggests that although purinergic remodeling exists in both
COPD and IPF patients, it is more likely that there is a causative
role for A2BR driven mediator expression in IPF than in COPD.
Alternatively, CD73 and A2BR differences might correlate with yet
uncharacterized responses that are more closely associated with
COPD, such as protease production. Thus, purinergic remodeling
responses in IPF and COPD exists to increase adenosine levels;
however, the downstream consequences likely differ amongst
disorders with different pathological manifestations.
Substantial evidence in mouse models of chronic lung disease
suggests that adenosine-based therapeutics are beneficial for the
treatment of chronic lung disease where airspace destruction and
fibrosis is prominent [7]. ADA replacement therapy consists of
intra-peritoneal or intranasal treatment with ADA conjugated to
polyethylene glycol. This therapy is able to prevent elevations in
adenosine, or lower the levels of elevated adenosine in various
models of lung disease [23,24,27,29]. Preventing elevations in
adenosine using this therapy can prevent and reverse airway
inflammation, fibrosis, and alveolar airspace enlargement. Thus,
adenosine elevations play an important role in accessing pathways
that lead to pulmonary fibrosis and airspace destruction. The
ADA-deficient model of adenosine-dependent pulmonary disease
has provided a useful mechanism for examining the contribution
of individual adenosine receptors to the inflammation and damage
seen in the lung in response to adenosine elevations. A recent study
used a selective A2BR antagonist (CVT-6883) to block this
receptor in ADA-deficient mice [30]. Treating ADA-deficient
mice with this antagonist prevented the production of numerous
mediators from alveolar macrophages, thus preventing the
development of airspace enlargement and pulmonary fibrosis
[30]. Treatment with CVT-6883 also prevented pulmonary
fibrosis in the bleomycin induced fibrosis model [30]. These
findings demonstrate that elevations in adenosine in the lung can
promote airspace enlargement and fibrosis in part by engaging the
A2BR. These findings in mouse models raised the possibility that
ADA replacement therapy and A2BR antagonist treatment may
benefit patients with airspace enlargement and pulmonary fibrosis.
In conclusion, findings in the current study suggest that
components of adenosine metabolism and signaling are altered
in a manner that promotes adenosine production in patients with
Stage 4 COPD and Severe IPF. These changes include the up-
regulation of CD73, a down-regulation of ADA activity, and
elevations in the A2BR. It provides proof of concept information
that human COPD and IPF patients may benefit from adenosine-
based therapeutics such as ADA enzyme replacement therapy or
treatment with an A2BR antagonist. In addition, monitoring
purinergic remodeling responses in lung samples provides an
attractive approach for screening patients for the potential
effectiveness of adenosine-based therapeutics.
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